On October 11, 2022 Enterome, a clinical-stage company developing first-in-class immunomodulatory drugs for cancer and inflammatory diseases based on its unique Mimicry platform, reported that Pierre Belichard, CEO, will present an overview of the Company and take part in 1-on-1 meetings with institutional investors at the following upcoming investor meetings (Press release, Enterome, OCT 11, 2022, View Source [SID1234621897]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Solebury / BMO Fall Private Company Showcase which will take place on Thursday, October 13, in New York (US)
– Enterome’s Corporate presentation will take place at 9.20 am EST.

Jefferies London Healthcare Conference which will take place November 15-17
Enterome’s Chief Business Officer, Anne Dagallier, will take part in 1-on-1 meetings with potential business partners at the Pharma Partnering US Summit which will take place in Boston, MA, on November 17 & 18.